|Strain Name||C57BL/6-Pdcd1tm1(PDCD1)Tnfrsf4tm1(TNFRSF4)/Bcgen||Common Name||B-hPD-1/hOX40 mice|
PD-1 (Programmed death-1) ；
TNFRSF4 （Tumor necrosis factor receptor superfamily, member 4, also known as OX40）
NCBI Gene ID
Protein expression analysis
Combination therapy of PD-1(pembrolizumab) Ab and OX40 Ab
Antitumor activity of anti-hOX40 antibody combined with anti-hPD-1 antibody pembrolizumab in B-hPD-1/hOX40 mice. (A) Anti-hOX40 antibody combined with anti-hPD-1 antibody pembrolizumab inhibited MC38 tumor growth in B-hPD-1/hOX40 mice. Murine colon cancer MC38 cells (5×105) were subcutaneously implanted into homozygous B-hPD-1/hOX40 mice (female, 6-7 week-old, n=6). Mice were grouped when tumor volume reached approximately 150±50 mm3, at which time they were treated with anti-hOX40 antibody combined with anti-hPD-1 antibody pembrolizumab with doses and schedules indicated in panel (B) Body weight changes during treatment. As shown in panel A, combination of anti-hOX40 and anti-hPD-1 antibody shows more inhibitory effects than individual groups, demonstrating that the B-hPD-1/hOX40 mice provide a powerful preclinical model for in vivo evaluating combination therapy efficacy of hOX40 antibodies and hPD-1 antibodies . Values are expressed as mean ± SEM.